Figure 2.

Dose-dependent binding of vedolizumab (VDZ) to α4β7 integrin-expressing different leukocyte subsets. (a) Quantitative flow cytometry of α4⁺β7⁺VDZ⁺ cells in different leukocyte subsets incubated with the indicated concentrations of fluorescently labeled VDZ. n = 15–20 per group. (b) Quantitative flow cytometry of α4⁺β7⁺VDZ⁺ cells in different leukocyte subsets compared between healthy controls (Ctrl) and patients with inflammatory bowel disease (IBD). n = 5–12 per group. Results depicted as bar graphs with SEM and single data points. Significant outliers were identified using the Grubbs test (P = 0.05) and excluded from analysis. Statistical comparisons were performed using Kruskal-Wallis with Dunn's multiple comparisons test (a) and 2-way ANOVA with Sidak's multiple comparisons test (b). *P < 0.05; **P < 0.01; ***P < 0.001.